Presentation is loading. Please wait.

Presentation is loading. Please wait.

A Prospective, Randomized Clinical Trial of Hemodynamic Support With Impella 2.5 Versus Intra-Aortic Balloon Pump in Patients Undergoing High-Risk Percutaneous.

Published byKerry Hudson Modified over 8 years ago

Similar presentations

Presentation on theme: "A Prospective, Randomized Clinical Trial of Hemodynamic Support With Impella 2.5 Versus Intra-Aortic Balloon Pump in Patients Undergoing High-Risk Percutaneous."— Presentation transcript:

1 A Prospective, Randomized Clinical Trial of Hemodynamic Support With Impella 2.5 Versus Intra-Aortic Balloon Pump in Patients Undergoing High-Risk Percutaneous Coronary InterventionClinical Perspective by William W. O'Neill, Neal S. Kleiman, Jeffrey Moses, Jose P.S. Henriques, Simon Dixon, Joseph Massaro, Igor Palacios, Brijeshwar Maini, Suresh Mulukutla, Vladimír Džavík, Jeffrey Popma, Pamela S. Douglas, and Magnus Ohman Circulation Volume 126(14):1717-1727 October 2, 2012 Copyright © American Heart Association, Inc. All rights reserved.

2 Study flow. William W. O'Neill et al. Circulation. 2012;126:1717-1727 Copyright © American Heart Association, Inc. All rights reserved.

3 Kaplan–Meier curves of major adverse events to 90 days. William W. O'Neill et al. Circulation. 2012;126:1717-1727 Copyright © American Heart Association, Inc. All rights reserved.

4 Prespecified prospectively defined subgroup analysis: intent-to-treat population. William W. O'Neill et al. Circulation. 2012;126:1717-1727 Copyright © American Heart Association, Inc. All rights reserved.

5 Prespecified prospectively defined subgroup analysis: per protocol population. William W. O'Neill et al. Circulation. 2012;126:1717-1727 Copyright © American Heart Association, Inc. All rights reserved.

6 Ninety-day major adverse events rates over the course of the trial (intent-to-treat population). William W. O'Neill et al. Circulation. 2012;126:1717-1727 Copyright © American Heart Association, Inc. All rights reserved.

Download ppt "A Prospective, Randomized Clinical Trial of Hemodynamic Support With Impella 2.5 Versus Intra-Aortic Balloon Pump in Patients Undergoing High-Risk Percutaneous."

Similar presentations

On behalf of all PROTECT II Investigators

On behalf of all PROTECT II Investigators
Trial profile Fox K et al. Lancet 2008;372:807-16.

Trial profile Fox K et al. Lancet 2008;372:
Clinic of Cardiovascular and Thorax Surgery Bad Rothenfelde, Germany

Clinic of Cardiovascular and Thorax Surgery Bad Rothenfelde, Germany
M Gaudino. 2 Loop FD et al NEJM 1986 Arterial conduits used for coronary artery bypass grafting - Internal Thoracic Artery - Radial Artery - Right.

M Gaudino. 2 Loop FD et al NEJM 1986 Arterial conduits used for coronary artery bypass grafting - Internal Thoracic Artery - Radial Artery - Right.
Genous™ endothelial progenitor cell capturing stent vs. the Taxus Liberté stent in patients with de novo coronary lesions with a high-risk of coronary.

Genous™ endothelial progenitor cell capturing stent vs. the Taxus Liberté stent in patients with de novo coronary lesions with a high-risk of coronary.
Flow of Patients Through the Trial Nissen SE, et al. JAMA 2008;299:1561-73.

Flow of Patients Through the Trial Nissen SE, et al. JAMA 2008;299:
Date of download: 5/30/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Elective Intra-aortic Balloon Counterpulsation During.

Date of download: 5/30/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Elective Intra-aortic Balloon Counterpulsation During.
Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Varespladib and Cardiovascular Events in Patients.

Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Varespladib and Cardiovascular Events in Patients.
Trends in Hospitalizations and Outcomes for Acute Cardiovascular Disease and Stroke, 1999–2011CLINICAL PERSPECTIVE by Harlan M. Krumholz, Sharon-Lise T.

Trends in Hospitalizations and Outcomes for Acute Cardiovascular Disease and Stroke, 1999–2011CLINICAL PERSPECTIVE by Harlan M. Krumholz, Sharon-Lise T.
Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38.

Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38.
Increased Risk for Heart Valve Disease Associated With Antiphospholipid Antibodies in Patients With Systemic Lupus ErythematosusClinical Perspective by.

Increased Risk for Heart Valve Disease Associated With Antiphospholipid Antibodies in Patients With Systemic Lupus ErythematosusClinical Perspective by.
Catheter Ablation of Atrial Fibrillation by Roderick Tung, Eric Buch, and Kalyanam Shivkumar Circulation Volume 126(2):223-229 July 10, 2012 Copyright.

Catheter Ablation of Atrial Fibrillation by Roderick Tung, Eric Buch, and Kalyanam Shivkumar Circulation Volume 126(2): July 10, 2012 Copyright.
Dietary and Policy Priorities for Cardiovascular Disease, Diabetes, and Obesity by Dariush Mozaffarian Circulation Volume 133(2):187-225 January 12, 2016.

Dietary and Policy Priorities for Cardiovascular Disease, Diabetes, and Obesity by Dariush Mozaffarian Circulation Volume 133(2): January 12, 2016.
Can Adenosine 5′-Triphosphate Be Used to Select Treatment in Severe Vasovagal Syndrome? by Daniel Flammang, Timothy Church, Marc Waynberger, Annick Chassing,

Can Adenosine 5′-Triphosphate Be Used to Select Treatment in Severe Vasovagal Syndrome? by Daniel Flammang, Timothy Church, Marc Waynberger, Annick Chassing,
Pulmonary artery catheterization in acute coronary syndromes: Insights from the GUSTO IIb and GUSTO III trials  Mauricio G. Cohen, MD, Robert V. Kelly,

Pulmonary artery catheterization in acute coronary syndromes: Insights from the GUSTO IIb and GUSTO III trials  Mauricio G. Cohen, MD, Robert V. Kelly,
Rationale and design of the Fractional Flow Reserve versus Angiography for Multivessel Evaluation (FAME) 3 Trial: A comparison of fractional flow reserve–guided.

Rationale and design of the Fractional Flow Reserve versus Angiography for Multivessel Evaluation (FAME) 3 Trial: A comparison of fractional flow reserve–guided.
Figure 2 Kaplan–Meier estimates of event-free survival (survival to the combined endpoint). From: Long-term outcomes of patients with acute myocardial.

Figure 2 Kaplan–Meier estimates of event-free survival (survival to the combined endpoint). From: Long-term outcomes of patients with acute myocardial.
Fatal and Nonfatal Cardiovascular Disease and the Use of Therapies for Secondary Prevention in a Rural Region of India by Rohina Joshi, Clara K. Chow,

Fatal and Nonfatal Cardiovascular Disease and the Use of Therapies for Secondary Prevention in a Rural Region of India by Rohina Joshi, Clara K. Chow,
Driving Times and Distances to Hospitals With Percutaneous Coronary Intervention in the United States by Brahmajee K. Nallamothu, Eric R. Bates, Yongfei.

Driving Times and Distances to Hospitals With Percutaneous Coronary Intervention in the United States by Brahmajee K. Nallamothu, Eric R. Bates, Yongfei.
Factors associated with postoperative atrial fibrillation and other adverse events after cardiac surgery  Emmanuel Akintoye, MD, MPH, Frank Sellke, MD,

Factors associated with postoperative atrial fibrillation and other adverse events after cardiac surgery  Emmanuel Akintoye, MD, MPH, Frank Sellke, MD,

Similar presentations

Ads by Google